Tevosol
Tevosol is an Edmonton, Canada-based medical device company founded in 2015 that developed the Ex-Vivo Organ Support System (EVOSS) to rehabilitate and expand the supply of transplantable donor organs for transplantation medicine.
- Company typePrivate
- Founded2015
- HeadquartersEdmonton, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Tevosol does
Tevosol is an Edmonton, Canada-based medical device company founded in 2015 that developed the Ex-Vivo Organ Support System (EVOSS), a platform intended to rehabilitate marginal donor organs and increase the supply of organs available for transplantation. The company positioned itself in the organ-preservation/transplantation medicine segment, with leadership pairing executive function (CEO Ron Mills) alongside clinical investigation depth (Vice President & Director of Clinical Investigation Jayan Nagendran). Tevosol operated with a small team of 1-10 employees and secured approximately $4.55M across three early-stage funding rounds in 2016 (with VA Angels participation), 2017 and 2019 from undisclosed investor bases.
The underlying business model relied on eventual commercialization of a regulated medical device to transplant centers and hospitals — a regulatory-intensive sales path with long development timelines and concentrated institutional buyers. No pricing, customer, distribution channel, partnership, certification, patent, or revenue data is disclosed in the available inputs. As of the supplied data, the company's tevosol.com web presence has been replaced by a HugeDomains domain-sale listing (priced at $5,695) and third-party data reports an operating status of 'closed,' indicating that the firm is not currently demonstrating active operations, customer engagement, or pipeline progression. The available evidence is insufficient to confirm continued independent operation or commercialization activity.
Tevosol firmographics
Firmographics- Name
- Tevosol
- Website
- https://tevosol.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Closed
- Headcount range
- 1–10 employees
- Short description
- Tevosol is an Edmonton, Canada-based medical device company founded in 2015 that developed the Ex-Vivo Organ Support System (EVOSS) to rehabilitate and expand the supply of transplantable donor organs for transplantation medicine.
- Ownership category
- akta.pro rank
Tevosol industry classification
Industry- Product category
- Organ Transplantation Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Blood and Organ Banks (621991)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)
- akta.pro secondary industry
- Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies) (HLAIAAAO)
Keywords
Where Tevosol is headquartered
LocationHeadquarters
- HQ city
- Edmonton
- HQ country
- Canada
- HQ region
- North America
Markets served
Tevosol business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Tevosol product offering
Product offeringCore offering
Tevosol has developed the Ex-Vivo Organ Support System, a medical device platform designed to preserve and support organs outside the body in order to increase the number of available organs for transplantation. The system is targeted at transplant programs and clinical investigators working to expand the supply of viable donor organs.
Product overview
Tevosol operates as a domain name listed for sale on HugeDomains.com. The single product offering is the domain name TeVosOl.com, a 7-character .com domain available for immediate purchase or via a 24-month payment plan at 0% interest. No other products, services, or company information is available for Tevosol in the source data.
Differentiator
Problem solved
Functional benefit
Companies that use Tevosol
Customer profileIdeal customer profiles1 record
Tevosol technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Tevosol partnerships and signals
Strategic signalRecent moves5 records
Expansion highlights2 records
Tevosol competitors and assessment
Company assessmentDirect peers
- OrganOx: OrganOx commercializes the metra normothermic liver perfusion device, a direct ex-vivo organ support system competing for the same transplant-center customers and clinical workflow as EVOSS.
- TransMedics: TransMedics develops the Organ Care System (OCS), the most advanced commercial ex-vivo organ preservation and assessment platform for lung, heart, and liver — the same clinical use case Tevosol's EVOSS targets.
- XVIVO Perfusion: XVIVO Perfusion offers machine perfusion and preservation solutions for lungs, kidneys, and hearts, making it a direct competitor in the ex-vivo organ support category where Tevosol operates.
- Organ Recovery Systems: Organ Recovery Systems' LifePort platform is a kidney perfusion device widely adopted by transplant centers — a direct functional peer to Tevosol's EVOSS in ex-vivo organ support.
- Paragonix Technologies: Paragonix develops advanced organ preservation and transport devices (e.g., LUNGguard, BAROguard), overlapping with Tevosol's mission of expanding usable donor organs through better preservation technology.
- Organ Assist: Organ Assist develops and supplies machine perfusion devices for kidneys, livers, and lungs, and is a direct competitor in the ex-vivo organ preservation space where Tevosol competes.
Regional players
- Institut Georges Lopez (IGL): IGL manufactures static cold preservation solutions widely used in European transplant centers, serving the same preservation workflow as Tevosol's device and representing a regional competitor in the same category.
Broad incumbents
- Thermo Fisher Scientific: Thermo Fisher supplies transplant diagnostics, cell-therapy manufacturing, and laboratory reagents that support transplant workflows — a broad incumbent with tangential overlap to Tevosol's transplant-focused device mission.
Emerging players
- Bridge to Life: Bridge to Life supplies organ preservation solutions and is expanding into device-based preservation, intersecting with Tevosol's ex-vivo organ support mission.
- Preservation Solutions: Preservation Solutions develops organ and tissue preservation chemistries used in transplant workflows, a partial-overlap emerging player in the broader organ preservation ecosystem.
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights4 records
Customer concentration
Tevosol social profiles
Digital presenceTevosol financial estimates
Financial estimateRevenue estimate
Valuation estimate
Tevosol leadership team
Management profileNumber of profiles
Profiles2 records
Tevosol funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Tevosol M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Tevosol
What does Tevosol do?
Tevosol has developed the Ex-Vivo Organ Support System, a medical device platform designed to preserve and support organs outside the body in order to increase the number of available organs for transplantation. The system is targeted at transplant programs and clinical investigators working to expand the supply of viable donor organs.
Is Tevosol a public or private company?
Tevosol is a private company. It is classified as venture growth investor backed and is currently closed.
When was Tevosol founded?
Tevosol was founded in 2015. It employs 1 to 10 people.
Where is Tevosol based?
Tevosol is headquartered in Edmonton, Canada, in the North America region.
Who are Tevosol's main competitors?
Direct peers on record are OrganOx, TransMedics, XVIVO Perfusion, Organ Recovery Systems, Paragonix Technologies and Organ Assist. Institut Georges Lopez (IGL) is listed as a regional player. Thermo Fisher Scientific is listed as a broad incumbent. Emerging players are Bridge to Life and Preservation Solutions.
Does Tevosol have an API?
No public API is recorded for Tevosol.
What industry is Tevosol in?
Tevosol's product category is Organ Transplantation Medical Devices. Its primary akta.pro industry code is HLAHAFAG, Mechanical Circulatory Support (VAD, IABP, ECMO), with a secondary code of HLAIAAAO, Transplantation & Advanced Therapies Pharmaceuticals (incl. Cell & Gene Therapies). Its NAICS code is 339112 and its SIC code is 3841.